Skip to content
Open access

Drug-coated balloons angioplasty versus drug-eluting stents for coronary artery bypass graft

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

TL;DR

Stentless PCI with DCB was frequently employed and demonstrated comparable one-year clinical outcomes to DES implantation for bypass graft lesions in patients undergoing PCI for bypass graft lesions.

Abstract

Graft failure following coronary artery bypass grafting (CABG) is a common clinical problem associated with adverse cardiovascular outcomes. Although percutaneous coronary intervention (PCI) for bypass graft lesions is frequently performed in clinical practice, the optimal device strategy remains debated. Recently, drug-coated balloon (DCB) has emerged as a potential stentless alternative. This study aimed to compare one-year clinical outcomes between DCB and drug-eluting stent (DES) in patients undergoing PCI for bypass graft lesions. Data were analysed from a nationwide PCI registry in Japan between 2017 and 2020. Patients who underwent PCI with DES or DCB for bypass graft lesions were included in the analysis. The primary endpoint was major adverse cardiovascular events (MACE), which were defined as a composite of all-cause death, acute coronary syndrome (ACS), and stroke within one year after PCI. The secondary endpoints included the individual components of MACE, major bleeding, and planned repeat revascularisation. Multivariable Cox proportional hazards models were used to compare outcomes, with subgroup analyses performed according to graft type (saphenous vein graft [SVG] or arterial graft [AG]). Of the 165,266 patients who underwent PCI during the study period, 780 patients underwent PCI for bypass graft lesions. After excluding 141 PCIs performed without DES or DCB, and 29 PCIs in which both DES and DCB were used, 610 PCIs were included in the final study cohort: 426 (69.8%) with DES and 184 (30.2%) with DCB alone. At one year after PCI, the incidence of MACE did not differ significantly between the DES and DCB groups (10.3% vs. 8.6%; P=0.69; Figure 1). Additionally, no significant differences were observed when outcomes were stratified by SVG or AG PCI (P=0.72 and P=0.91, respectively; Figure 1). Similarly, there were no significant differences in all-cause death (P=0.57), cardiovascular death (P=0.71), non-fatal ACS (P=0.73), non-fatal stroke (P=0.22), non-fatal major bleeding (P=0.19), and planned repeat revascularisation (P=0.33) between the DES and DCB groups (Figure 2). After multivariable adjustment, the risk of MACE was comparable for DCB and DES (adjusted hazard ratio, 1.01; 95% confidence interval, 0.58-1.76; P=0.96). Stentless PCI with DCB was frequently employed and demonstrated comparable one-year clinical outcomes to DES implantation for bypass graft lesions.Fig. 1.KM curves for MACE incidenceFor image description, please refer to the figure legend and surrounding text.Fig. 2.KM curves for secondary outcomesFor image description, please refer to the figure legend and surrounding text.

Read PDF

Similar papers

Oct 2026

Drug coated balloon vs. drug eluting stent in calcified de novo coronary lesions: Long term outcomes from the SPARTAN registry.

AIM Coronary artery calcification presents major challenges during PCI, including device deliverability, suboptimal lesion preparation, impaired stent expansion, increased restenosis, stent thrombosis and mortality. Drug-coated balloons (DCB) offer a stent-less alternative, but evidence in de novo calcified lesions is...

Rajkumar Natarajan, N. Corballis, I. Merinopoulos et al. · 0 citations
Open access Sep 2026

Ten-year outcomes after percutaneous coronary intervention with drug-eluting stents for bifurcation lesions: insights from the DECADE cooperation.

Patients treated with percutaneous coronary intervention (PCI) for bifurcation lesions have an increased risk of recurrent cardiac events. However, there are limited data on long-term outcomes after PCI with drug-eluting stents (DES) for bifurcation lesions. We sought to compare the long-term outcomes after DES PCI for...

Constantin Kuna, Laura Huber, J. Coughlan et al. · 0 citations
Open access Oct 2026

Outcomes following percutaneous coronary revascularisation in acute coronary syndromes: a comparison of drug coated balloon versus drug eluting stent strategies in de novo large epicardial vessels

The medium-term clinical outcome following the use of a DCB only strategy in large vessel in ACS patient population was comparable to a DES only strategy, which was comparable to a DES only strategy.

H. Khan, M. Egred, M. Alkhalil et al. · 0 citations
Nov 2026

Long-term outcomes after percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting for left main coronary artery disease: a prospective analysis of the multicentre IRIS-MAIN registry.

BACKGROUND Percutaneous coronary intervention (PCI) with drug-eluting stents has been widely used to treat patients with left main coronary artery disease; however, long-term comparative outcomes versus coronary artery bypass grafting (CABG) in real-world populations remain poorly characterised. We aimed to compare lon...

Seong-Bong Wee, D. Kang, Jung-Min Ahn et al. · 1 citation
Open access Oct 2026

Safety and effectiveness of drug-coated balloon angioplasty in de novo coronary lesions: 6-month outcomes from a multicenter registry

Drug-coated balloon (DCB) angioplasty has emerged as a promising alternative to drug eluting stent (DES) implantation, particularly in small-vessel coronary disease (defined as target vessels with a reference diameter ≤2.75 mm). Nevertheless, multicenter real-world data focusing exclusively on de novo lesions remain...

N. Tsiamis, A. Papanikolaou, F. Toulgaridis et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.